Ovarian Cancer Drug Approved by NHS

A new life-prolonging treatment for advanced ovarian cancer has been approved for use on the NHS in England, marking the first new drug for chemotherapy-resistant ovarian cancer in 20 years.

This offers fresh hope for hundreds of women, particularly those with platinum-resistant disease.

The drug, Elahere, developed by AbbVie, represents a significant advancement in precision oncology.

This approval underscores the ongoing efforts to provide innovative treatments for challenging cancers and improve patient outcomes.